Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide

Form I of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide, wherein an X-ray powder diffractogram of the Form I comprises diffraction angles expressed in degrees 2-theta (2θ) at:

• 5.3, 10.7, 13.9, and 14.6, each of the diffraction angles having an error of about ±0.2 degrees (2θ).

A pharmaceutical composition, comprising an effective amount for treating colorectal cancer of Form I of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide, wherein an X-ray powder diffractogram of the Form I comprises diffraction angles expressed in degrees 2-theta (2θ) at:

• 5.3, 10.7, 13.9, and 14.6, each of the diffraction angles having an error of about ±0.2 degrees (2θ), and at least one pharmaceutically acceptable carrier.

A method of treating colorectal cancer in a subject in recognized need thereof, comprising administering to said subject an effective amount of the Form I of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide, wherein an X-ray powder diffractogram of the Form I comprises diffraction angles expressed in degrees 2-theta (2θ) at:

• 5.3, 10.7, 13.9, and 14.6, each of the diffraction angles having an error of about ±0.2 degrees (2θ).

A pharmaceutical composition comprising a crystalline form of the compound of Formula A

• which has an x-ray powder diffraction pattern when measured using a CuKαradiation comprising peaks expressed in degrees 2-theta (2θ) at 5.3±0.2, 10.7±0.2, 13.9±0.2, and 14.6±0.2;
• and a pharmaceutically acceptable carrier;
• wherein the content of other crystalline forms of the compound of Formula A in said pharmaceutical composition is less than 40% by weight.